Joint HOVON-50/GMMG-HD3 randomized trial on the effect of thalidomide as part of a high-dose therapy regimen and as maintenance treatment for newly diagnosed myeloma patients
暂无分享,去创建一个
H. Goldschmidt | P. Sonneveld | A. Glasmacher | A. Ho | A. Benner | I. Schmidt-Wolf | H. Lokhorst | D. Hoelzer | B. Holt | I. Breitkreutz | F. Cremer | P. Westveer | H. Martin
[1] N. Kröger,et al. Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma. , 2002, Blood.
[2] B. Barlogie,et al. Improved outcome of allogeneic transplantation in high-risk multiple myeloma patients after nonmyeloablative conditioning. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] C. Craddock,et al. Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen. , 2002, Blood.
[4] H. Goldschmidt,et al. Salvage therapy for multiple myeloma with thalidomide and CED chemotherapy. , 2001, Blood.
[5] H. Goldschmidt,et al. Angiogenesis in hematologic malignancies , 2001, Annals of Hematology.
[6] B. Barlogie,et al. Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. , 2001, Blood.
[7] G. Gahrton,et al. Progress in allogeneic bone marrow and peripheral blood stem cell transplantation for multiple myeloma: a comparison between transplants performed 1983–93 and 1994–98 at European Group for Blood and Marrow Transplantation centres , 2001, British journal of haematology.
[8] H. Goldschmidt,et al. Alpha-interferon maintenance treatment is associated with improved survival after high-dose treatment and autologous stem cell transplantation in patients with multiple myeloma: a retrospective registry study from the European Group for Blood and Marrow Transplantation (EBMT) , 2001, Bone Marrow Transplantation.
[9] H. Goldschmidt,et al. High plasma basic fibroblast growth factor concentration is associated with response to thalidomide in progressive multiple myeloma. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[10] G. Juliusson,et al. Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma. , 2000, British journal of haematology.
[11] H. Ludwig,et al. Interferon-alpha treatment in multiple myeloma: meta-analysis of 30 randomised trials among 3948 patients. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.
[12] G Muller,et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. , 2000, Blood.
[13] S. Rajkumar,et al. A review of angiogenesis and antiangiogenic therapy with thalidomide in multiple myeloma. , 2000, Cancer treatment reviews.
[14] A. Chott,et al. Multiple myeloma with deletion of chromosome 13q is characterized by increased bone marrow neovascularization , 2000, British journal of haematology.
[15] A. Dispenzieri,et al. Thalidomide in the treatment of relapsed multiple myeloma. , 2000, Mayo Clinic proceedings.
[16] G. van Kaick,et al. Funktioelle Magnetresonanztomographie in Diagnostik und Therapiemonitoring beim Multiplen Myelom , 2000, Der Radiologe.
[17] Y. Hattori,et al. [Bone marrow angiogenesis in multiple myeloma: new insights into the pathogenesis, and development of a new therapeutic approach]. , 2000, [Rinsho ketsueki] The Japanese journal of clinical hematology.
[18] Levi,et al. Therapy with thalidomide in refractory multiple myeloma patients — the revival of an old drug , 2000, British journal of haematology.
[19] B. Barlogie,et al. Antitumor activity of thalidomide in refractory multiple myeloma. , 1999, The New England journal of medicine.
[20] E. Holmberg,et al. Survival in conventionally treated younger (<60 years) multiple myeloma patients: no improvement during two decades , 1999, European journal of haematology.
[21] J. Baars,et al. Vincristine, doxorubicin and dexamethasone (VAD) administered as rapid intravenous infusion for first‐line treatment in untreated multiple myeloma , 1999, British journal of haematology.
[22] M. Gore,et al. A randomized trial of maintenance interferon following high‐dose chemotherapy in multiple myeloma: long‐term follow‐up results , 1998, British Journal of Haematology.
[23] B. Barlogie,et al. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. , 1997, Blood.
[24] J. Rossi,et al. A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple Myeloma , 1996 .
[25] B. Barlogie,et al. Peripheral blood stem cell transplants for multiple myeloma: identification of favorable variables for rapid engraftment in 225 patients. , 1995, Blood.
[26] M. Dimopoulos,et al. The treatment of multiple myeloma. , 1994, The New England journal of medicine.
[27] W. Gregory,et al. Combination chemotherapy versus melphalan and prednisolone in the treatment of multiple myeloma: an overview of published trials. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] D. Vesole,et al. High-dose therapy in multiple myeloma. , 2003, Blood.
[29] A. Levis,et al. Low-dose of thalidomide in the treatment of refractory myeloma. , 2000, Haematologica.
[30] B. Barlogie,et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma. , 1999, Blood.
[31] B. Barlogie,et al. High-dose therapy for refractory multiple myeloma: improved prognosis with better supportive care and double transplants. , 1994, Blood.